Table VIII.

Univariate and multivariate Cox analyses for OS and PRFS in patients with stage III gastric cancer.

A, OS
	Univariate analysis			Multivariate analysis
Variables	Regression coefficient	Hazard ratio (95% CI)	P-value	Regression coefficient	Hazard ratio (95% CI)	P-value
Sex	−0.28	0.76 (0.43–1.38)	0.352
Tumor size	−0.05	0.95 (0.52–1.84)	0.864
Lymph node metastasis	1.54	4.69 (1.03–82.91)	0.045	1.26	3.54 (0.74–63.31)	0.131
Lymphatic invasion	0.48	1.61 (0.74–4.23)	0.243
Venous invasion	0.44	1.72 (0.71–3.85)	0.234
Differentiation	−0.10	0.90 (0.40–2.60)	0.833
ex-miR-21	0.89	2.42 (1.40–4.31)	0.014	1.26	3.54 (1.74–3.31)	0.025
ex-miR-92a	−0.65	0.52 (0.30–0.89)	0.017	−0.55	0.58 (0.33–0.99)	0.047
B, PRFS
	Univariate analysis			Multivariate analysis
Variables	Regression coefficient	Hazard ratio (95% CI)	P-value	Regression coefficient	Hazard ratio (95% CI)	P-value
Sex	−0.01	0.99 (0.56–1.86)	0.962
Tumor size	1.79	5.99 (1.32–5.94)	0.041	1.41	4.11 (0.87–7.36)	0.080
Lymph node metastasis	0.58	1.78 (0.83–4.65)	0.150
Lymphatic invasion	0.38	1.47 (0.75–3.21)	0.273
Venous invasion	−0.24	0.79 (0.35–2.27)	0.625
Differentiation	0.81	2.26 (1.33–3.94)	0.024	0.87	2.07 (1.41–3.98)	0.028
ex-miR-21	−0.56	0.57 (0.34–0.96)	0.033	−0.43	0.51 (0.28–0.91)	0.044
ex-miR-92a

ex-, exosome-encapsulated; miR, microRNA; OS, overall survival; PRFS, peritoneal recurrence-free survival.